BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

The firm said its next-generation siRNA candidate showed in preclinical studies that it could reduce tumor growth and metastatic spread.

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC).

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

Suzhou Zion Pharma Technology Co. Ltd. has identified GTPase KRAS G12D or G13D mutant and/or KRAS inhibitors reported to be useful for the treatment of cancer.

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic ... revealing a potential new treatment strategy for this ...

Silexion Therapeutics (SLXN) announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates ...

Mutant KRAS in ctDNA in patients with localized pancreatic cancer was shown to be a biomarker for metastatic progression and ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...